Jovan-Embiricos Morana

CIK 00015757454 companiesBERKELEY HEIGHTS, NJ

SEC Profile

Transactions

Companies

Filings

CIK

0001575745

Recent Transactions

50 trades

Award
Kalaris Therapeutics, Inc.$KLRS
Stock Option (Right to Buy)
2026-06-03+9,000→ 9,000 total
Award
Kalaris Therapeutics, Inc.$KLRS
Stock Option (Right to Buy)
2025-04-10+18,000→ 18,000 total
Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2024-06-06+35,000→ 100,197 total
Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2023-05-11+35,000→ 65,197 total
Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2022-07-28$4.61/sh+325,379→ 668,072 total
Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2022-07-28$4.61/sh+867,678→ 867,678 total
Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2022-07-28$4.61/sh+684,622→ 2,059,884 total
Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2022-07-28$4.61/sh+1,393,874→ 4,193,874 total
Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2022-07-28$4.61/sh+1,626,898→ 2,038,583 total
Award
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2022-07-28$4.61/sh+3,253,796→ 16,674,766 total
Exercise/Conversion
Cullinan Therapeutics, Inc.$CGEM
Stock Option (Right to Buy)
2022-06-24−104,845→ 0 total
Exercise/Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2022-06-24$4.30/sh+35,529→ 252,881 total
Exercise/Conversion
Cullinan Therapeutics, Inc.$CGEM
Stock Option (Right to Buy)
2022-06-24−35,529→ 0 total
Exercise/Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2022-06-24$4.30/sh+104,845→ 217,352 total
Tax Payment
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2022-06-24$13.39/sh−45,078→ 207,803 total
Award
Kalaris Therapeutics, Inc.$KLRS
Stock Option (Right to Buy)
2022-05-17+27,500→ 27,500 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-11-10$24.77/sh−680→ 1,375,262 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-11-10$24.77/sh−120→ 342,693 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-11-09$24.79/sh−572→ 342,813 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-11-09$24.79/sh−3,243→ 1,375,942 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-11-05$24.80/sh−1,257→ 343,385 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-11-05$24.80/sh−7,124→ 1,379,185 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-10-27$24.78/sh−330→ 344,642 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-10-27$24.78/sh−1,870→ 1,386,309 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-10-25$24.82/sh−6,604→ 1,388,179 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-10-25$24.82/sh−1,165→ 344,972 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-10-22$24.77/sh−859→ 346,137 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-10-22$24.77/sh−4,864→ 1,394,783 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-10-21$24.75/sh−85→ 1,399,647 total
Sale
Kalaris Therapeutics, Inc.$KLRS
Common Stock
2021-10-21$24.75/sh−15→ 346,996 total
Award
Cullinan Therapeutics, Inc.$CGEM
Stock Option (Right to Buy)
2021-09-16+7,800→ 7,800 total
Award
Kalaris Therapeutics, Inc.$KLRS
Stock Option (Right to Buy)
2021-05-25+22,500→ 22,500 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2021-01-12+71,599→ 71,599 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Series A Convertible Preferred Stock
2021-01-12−4,500,000→ 0 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Series A Convertible Preferred Stock
2021-01-12−20,500,000→ 0 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Series Seed Convertible Preferred Stock
2021-01-12−8,000,000→ 0 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Series B Convertible Preferred Stock
2021-01-12−3,205,128→ 0 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2021-01-12+182,135→ 182,135 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Series C Convertible Preferred Stock
2021-01-12−1,511,966→ 0 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Series C Convertible Preferred Stock
2021-01-12−1,007,977→ 0 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Series C Convertible Preferred Stock
2021-01-12−503,988→ 0 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2021-01-12+455,338→ 455,338 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2021-01-12+639,295→ 639,295 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2021-01-12+2,912,345→ 2,912,345 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2021-01-12+1,136,525→ 1,136,525 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Series C Convertible Preferred Stock
2021-01-12−503,988→ 0 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Series B Convertible Preferred Stock
2021-01-12−1,282,051→ 0 total
Purchase
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2021-01-12$21.00/sh+95,238→ 622,175 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2021-01-12+214,798→ 214,798 total
Conversion
Cullinan Therapeutics, Inc.$CGEM
Common Stock
2021-01-12+143,198→ 325,333 total

Companies

Recent Filings

Address

C/O KALARIS THERAPEUTICS, INC. 400 CONNELL DRIVE, SUITE 5500

BERKELEY HEIGHTS, NJ, 07922

View on SEC.gov